Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab response predictors in ulcerative colitis
NL-OMON44411Active, not recruiting
- Sponsor
- Rijnstate
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of vedolizumab in autoimmune colitis and inflammatory bowel disease (IBD), sponsored by Rijnstate. Started Jan 2018; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON44411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44411.